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PACAP and its role in primary headaches
Lars Edvinsson1*, János Tajti2, Levente Szalárdy2 and László Vécsei2,3
Abstract
Pituitary adenylate cyclase-activating peptide (PACAP) is a neuropeptide implicated in a wide range of functions,
such as nociception and in primary headaches. Regarding its localization, PACAP has been observed in the sensory
trigeminal ganglion (TG), in the parasympathetic sphenopalatine (SPG) and otic ganglia (OTG), and in the brainstem
trigeminocervical complex. Immunohistochemistry has shown PACAP-38 in numerous cell bodies of SPG/OTG,
co-stored with vasoactive intestinal peptide (VIP), nitric oxide synthase (NOS) and, to a minor degree, with choline
acetyltransferase. PACAP has in addition been found in a subpopulation of calcitonin gene-related peptide (CGRP)-
immunoreactive cells in the trigeminal system. The PACAP/VIP receptors (PAC1, VPAC1, and VPAC2) are present in
sensory neurons and in vascular smooth muscle related to the trigeminovascular system. It is postulated that
PACAP is involved in nociception. In support, abolishment of PACAP synthesis or reception leads to diminished
pain responses, whereas systemic PACAP-38 infusion triggers pain behavior in animals and delayed migraine-like
attacks in migraine patients without marked vasodilatory effects. In addition, increased plasma levels have been
documented in acute migraine attacks and in cluster headache, in accordance with findings in experimental
models of trigeminal activation. This suggest that the activation of the trigeminal system may result in elevated
venous levels of PACAP, a change that can be reduced when headache is treated. The data presented in this
review indicate that PACAP and its receptors may be promising targets for migraine therapeutics.
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Background
The field of PACAP and its receptor PAC1 is currently
very topical in the migraine field. Here we have provided
an overview of available data bases; we used PubMed,
Medline and Google Schoolar as sources. We report that
PACAP is released in conjunction of migraine and
cluster headache attacks. The most likely source of
PACAP contributing to this elevation in cranial outflow
resides in the trigeminovascular system (TVS) and the
parasympathetic otic and sphenopalatine ganglia. The
PAC1 receptor is less well described in the TVS, but
found in the trigeminal and sphenopalatine ganglia. It is
hypothesized that this may be a second neuropeptide
system that might be useful to block in acute attacks.
Introduction
Migraine is thought to involve a primary dysregulation
of sensory processing in the central nervous system
(CNS) as a starting point of migraine [1]. It is thought
that the origin of the disease rests in the hypothalamus
– thalamus system, coupling to the brainstem. The cen-
tral involvement is reflected early in many patients ex-
periencing tactile allodynia and other neurological
symptoms that affect the senses, including sensitivity to
light, sound, and smell. These are thought to be conse-
quences of central sensitization within the trigemino-
thalamic pathway. The trigeminovascular system is in-
volved with all its parts; the trigeminal nerve, the cranial
vasculature, and nuclei within the brainstem/spinal cord.
Pituitary adenylate cyclase-activating polypeptide
(PACAP) and vasoactive intestinal peptide (VIP) are
members of the VIP/secretin/growth hormone-releasing
hormone/glucagon neuropeptide superfamily, widely
expressed in vertebrate tissues [2–6]. VIP was first de-
scribed by Victor Mutt during the early 1970s [7]. It was
isolated from pig intestine and is localized to most or-
gans and tissues in the body. During the following years,
the other members of the family were described and
characterized, including peptide histidine isoleucine/me-
thionine (PHI/PHM), secretin, and PACAP [3, 8, 9]. The
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PACAP neuropeptide was discovered nearly 30 years ago
based on its ability to enhance adenylate cyclase activity
in rat pituitary cells, and was first isolated from ovine
hypothalamic extracts [10]. Numerous studies on the
localization/distribution/release of this group of neuro-
peptides from different tissues and involvement in dis-
eases have been presented [11, 12]. The aim of this
review is to focus on sensory aspects of PACAP and
primary headaches, with special emphasis on migraine.
General features and localization of PACAP within the
CNS
There are two forms of PACAP (− 27 and − 38), with both
isoforms sharing functional and structural homologies
with VIP [10] and being able to bind to G-protein-coupled
receptors specific (PAC1) and less specific (VPAC1 and
VPAC2; with comparable affinity to VIP, PACAP-27, and
PACAP-38) to PACAP [3, 13, 14]. Recently, however, the
functional presence of yet unidentified PACAP receptors
have been proposed based on experimental results using
selective modulators [15].
PACAP is a pleiotropic peptide that can be found in
several exocrine and endocrine tissues, in the respiratory,
intestinal, urinary, and reproductive systems, as well as in
the central and peripheral nervous systems [16–23]. In
neuronal tissues, the isoform PACAP-38 predominates. It
is known to play hypophysiotropic, neuromodulatory, and
neurotransmitter roles, and has been associated with
differentiation- and proliferation-inducing effects in the
developing nervous system, as well as with cytoprotective,
anti-apoptotic, and anti-inflammatory features within
various target organs [24–34]. Furthermore, PACAP has
been shown to be a potent local and systemic vasodilator
administered in a wide concentration range, associating
with biphasic paradoxical hypertensive effects in very large
doses [35–37].
Immunohistochemical evidence confirms the presence
of PACAP in anatomical structures relevant to the patho-
genesis of primary headaches including migraine, such as
in the trigeminocervical system, including nerve fibers in
the dura mater, the cerebral vessels [38], the facial skin
[39], the trigeminal ganglion (TG) [15, 39–44], the trigem-
inal nucleus caudalis (TNC) [15, 16, 45], the Rexed 1 and
2 laminae at the C1-C2 levels of the cervical spinal cord
[45] and in various brainstem nuclei within the ‘migraine
generator area’ [16, 46, 47] as well as in the parasympa-
thetic sphenopalatine (SPG) and otic ganglia (OTG) [40,
41, 48–50]. Recent works have revealed that PACAP is lo-
calized in small neurons in the dorsal root ganglia and the
TG which in addition store calcitonin gene-related peptide
(CGRP) [44]. Interestingly PACAP mRNA-labeled
neurons constituted 10% of the total number of nerve cell
bodies in the dorsal root ganglia, whereas the population
of CGRP mRNA-labeled nerve cell bodies constituted
46% [51]. This agrees well with later in depth immuno-
cytochemistry work on the TG [52] (Fig. 1).
In line with the above, early studies revealed the pres-
ence of specific PACAP-binding sites in relevant regions
of the rat and human CNS [53, 54]. In addition, subse-
quent immunohistochemical and biochemical evidence
demonstrated the presence of PAC1 and VPAC2 receptors
in the rat TG [55]. Of note, there exist some discordant
results, functional [56] and biochemical data on the
mRNA level suggest that VPAC1 receptors are not present
in the TG of rats [55]. However, mRNA for all three types
of VIP/PACAP receptors have been reported to occur in
human and rat TG [57], and this is supported by another
study in rat TG and TNC [15]. Moreover, protein expres-
sion has been shown by immunohistochemistry for all
three types of PACAP receptors in both the human and
rat SPG [49]. The evidence suggest a special role in terms
of disease pathogenesis among relevant neuropeptides.
The detailed histochemistry revealed that while VIP/
PACAP are both seen in the parasympathetic ganglia
(SPG/OTG), only PACAP has been found in the trigemi-
nal system [42].
Early findings of neuropeptide release in primary
headaches
The role of PACAP and VIP is under discussion because
(i) they appear jointly in most of the SPG/OTG neurons
and (ii) PACAP co-localizes with CGRP only in a small
fraction of neurons within the TG in the small to
medium sized neurons. Early studies showed that in
migraine VIP was only released in a subpopulation of
patients that had facial symptoms such as nasal conges-
tion, rhinorrhea, and scleral injection in addition to
headache (probably due to the activation of the parasym-
pathetic system). Importantly, all cluster headache sub-
jects showed both facial symptoms and VIP release [58];
however, at that time, the methodology to measure
PACAP was not available. We suggested that this was
due to activation of the parasympathetic system. Experi-
mental studies in cats [59] revealed that the activation of
the trigeminal system may in addition involve the para-
sympathetic system, as denervation of the trigeminal
nerve aborted the activation of SPG, interpreted either
as a direct or indirect coupling between these two
systems.
Involvement of PACAP in migraine
Conclusions from the studies with PACAP infusion and
knockouts
Human provocation studies of migraine using systemic
administration of different molecules have generated im-
portant insights into the possible mechanisms in primary
headache diseases. CGRP, VIP, and PACAP-38 are all
strong vasodilators, sharing the activation of adenylate
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cyclase. The first direct evidence that highlighted the po-
tential significance of PACAP in the pathophysiology of
migraine came from observations made in a human
study [60] where intravenous administration of
PACAP-38 caused headache and vasodilation in
healthy subjects as well as in migraineurs, and lead to
delayed-type migraine-like attacks exclusively in mi-
graine patients without aura (65–75%), a feature re-
markably similar to that previously reported after
nitroglycerin infusion [61, 62]. Because VIP had no
such effect, it was suggested that this might be sec-
ondary to the activation of the PAC1 receptor, which
is now under study in a clinical trial. For comparison,
CGRP induces delayed migraine-like attacks in 65% of
migraine patients, but not in normal subjects [63].
Today numerous CGRP active agents are on the verge
of going to the market as effective therapy both for
acute treatment and as prophylaxis.
In support of the above, a magnetic resonance imaging
(MRI) angiographic study revealed that PACAP-38-
induced headache was associated with significant dilation
of the extracranial part of the middle meningeal arteries
(MMAs), but not of the middle cerebral arteries (MCAs).
This effect preceded the onset of migraine-like headache
and was sensitive to the administration of a triptan class
of drug [64]. A subsequent MRI angiographic human
study demonstrated a remarkable and sustained vasodila-
tion of extracranial but not intracranial arteries (including
the MCAs) following PACAP-38 administration [65]. In
addition to these, intravenous PACAP-38-induced
migraine-like attacks have been found associated with
alterations in brain network connectivity, by means of a
resting-state functional MRI study [66]. The role of VIP in
PACAP-induced vasodilation is unclear, as data regarding
its levels after PACAP administration are contradictory
[65, 67], and its vasodilation is less long-lasting than that
of PACAP [65]. The migraine response to PACAP-38 has
not been found to be influenced by the presence of the
risk allele MEF2D [67, 68].
Experimental studies support the relevance of PACAP
in sensory functions as well as in pain disorders, includ-
ing primary headaches. Neurograms obtained following
stimulation of the ipsilateral peroneal or sciatic nerve
suggested that intrathecal PACAP may act as a neuro-
transmitter or modulator in sensory C-fibers, possibly
with a contribution of A-fibers [69]. Interestingly,
PACAP-27 was more potent than PACAP-38 or VIP at
this function. On the other hand, the direct intrathecal
administration of PACAP elicited a dose-dependent
decrease in the tail-flick latency, whereas higher doses
resulted in biting and scratching; these behaviors were
interpreted as pain-like syndrome and supported a role
of PACAP as a sensory neurotransmitter involved in
nociception [70]. Intrathecal administration of
PACAP(6–38), a PAC1 receptor antagonist reduced
mechanical and thermal hyperalgesia, suggesting that
these receptors are important for PACAP-induced pain
[71]. The role of PAC1 receptor in pain sensation has
also been supported by studies using PAC1 knockout
mice, as these animals showed reduced chronic
Fig. 1 Immunohistochemical demonstration of distribution of PACAP and CGRP in the sphenopalatine ganglion (SPG) and the trigeminal
ganglion (TG). The figures illustrates that in both ganglia there are cells storing the two neuropeptides and also being alone. The CGRP
immunoreactivity occurs more frequent in the TG than does PACAP-ir. Arrows show CGRP positive and PACAP negative cells, while arrow heads
show co-localization (above) or negative (below). There are also fibers positive to CGRP. In the SPG the arrow shows a single CGRP positive cell
that co-localize PACAP while numerous cells are positive to PACAP only (arrow head). In the right hand SPG illustration there are several CGRP
positive fibers
Edvinsson et al. The Journal of Headache and Pain  (2018) 19:21 Page 3 of 7
responses to chemical, mechanical, and thermal stimuli
[72, 73]. Similar results were obtained with PACAP-
knockout mice, presenting with diminished light-
aversive behavior (i.e., photophobia), decreased c-fos
expression in the TNC and TG, and reduced meningeal
blood flow following nitroglycerin administration
compared to wild-type controls [74].
PACAP has also been implicated in higher order
processing of pain in brain regions such as thalamus and
amygdala [75, 76], relevant in the central sensitization
and emotional load of pain. Intracerebroventricularly
applied PAC1 receptor inhibitor decreased the delayed
activation and sensitization of second-order nociceptive
neurons within the trigeminocervical complex following
dural stimulation [77]. This supports a potential role of
PACAP in the development of central sensitization of
pain in migraine. There are experimental results suggest-
ing the role of PACAP in the development of peripheral
sensitization as well in certain models of pain [78]. The
data on the possible role of PACAP and its receptors in
migraine pathogenesis by means of modulating neuro-
genic inflammation [73, 79–81] and mast cell degranula-
tion [65, 82–86] are, however, conflicting.
PACAP as a biomarker in primary headaches
A support for a sensory role of PACAP in nociception
came from experiments with capsaicin administration in
vivo in rats [26], as it resulted in elevated cerebrospinal
fluid concentrations of PACAP-27 by 177%, PACAP-38
by 93%, and CGRP by 692% [87]. Studies on animal
models of trigeminal activation confirm the potential
role of PACAP in the pathogenesis of migraine in par-
ticular, as immunoreactivity of both PACAP-27 and
PACAP-38 were found elevated in the TNC of rats fol-
lowing electrical stimulation (at the TG) or chemical
stimulation (by nitroglycerin) of the trigeminovascular
system [88]. Furthermore, PACAP-38 levels were found
elevated in the blood plasma of rats after electrical
stimulation of the TG [88]. Likewise, elevated levels of
PACAP were measured in the external jugular vein
samples of cats following electrical stimulation of the
superior sagittal sinus [89]. In fact, stimulation of the tri-
geminal system directly showed the release of not only
PACAP but also VIP and CGRP into the external jugular
venous blood [89, 90].
Human clinical studies provide concordant data, as of
note, elevated levels of plasma PACAP-38 were revealed
in the ictal period of migraineurs (i.e., during a spontan-
eous migraine attack) compared to the interictal phase
[89, 91]. Interestingly, supportive data were reported in
episodic cluster headache patients as well [92]. The
interictal plasma PACAP concentrations of migraineurs
were, however, significantly lower compared to the levels
measured in healthy controls or in patients with
tension-type headache [89, 91, 93].
Concluding remarks
The exact role of PACAP in primary headaches is still
unknown but it is clearly present in many different parts
of the CNS including several regions of interest in the
discussions of migraine pathophysiology. Current evi-
dence suggest that PACAP plays essential roles in the
pathogenesis of migraine via modulating the function of
nociceptive neurons within the trigeminocervical system.
The position of PACAP in migraine rests on the
following main observations: (i) PACAP levels are in-
creased in the circulation of cats and rats upon stimula-
tion of the superior sagittal sinus [89, 94], and the TG,
respectively [88]. (ii) PACAP levels in the external jugu-
lar vein are reduced with amelioration of migraine head-
ache when subjects were treated with sumatriptan, and
lower levels of PACAP occur between attacks when
compared with attacks [89]. (iii) Systemic infusion of
PACAP-38 in migraine patients results in migraine-like
headache [60]. (iv) The plasma levels of PACAP-38 are
altered in ictal and interictal periods of migraine patients
[91]. The unanswered questions that remain are related
to the origin of endogenous PACAP and the mechanism
through which systemic PACAP can induce migraine.
Though Banks suggests that PACAP has actions in the
CNS and provides evidence in support [95], the available
data strongly indicate that PACAP does not pass the wall
of cerebral arteries, as studied in isolated perfused
MCAs [96], which agrees with the view that the peptide
is a large molecule that does not pass the blood-brain
barrier (BBB) [96, 97]. Therefore, as suggested also for
CGRP, the relevant target of systemically administered
PACAP could very well be effects on sites located out-
side the BBB, such as the TG and other ganglia as well
as the dura mater; however, this is still not settled, and
the role of the BBB needs to be clarified.
Conclusions
1. The concordant experimental and clinical data show
that PACAP and its receptors may have a role in the
pathogenesis of primary headaches, especially
migraine and cluster headache.
2. The relation with other neuronal messenger
molecules deserves future study.
3. Collectively the current understanding of PACAP
and its receptors in relation intracranial structures
and brain provide valuable information as potential
targets of effective future therapeutics.
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